<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089595</url>
  </required_header>
  <id_info>
    <org_study_id>FER-SAR-023</org_study_id>
    <nct_id>NCT01089595</nct_id>
  </id_info>
  <brief_title>Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)</brief_title>
  <official_title>Open Label Phase II Randomized Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or in Combination With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced GIST That Have Progressed on High Dose Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced GIST are treated with imatinib. This study seeks to look at a new
      therapeutic agent at the time of tumor progression following treatment with 600-800 mg daily
      of imatinib. The study is looking to see if Nilotinib (tasigna) alone or in combination with
      imatinib (gleevec) is more effective at controlling disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resistance to imatinib does develop and represents a major clinical challenge. Mechanisms
      implicated in imatinib resistance include: target resistance due to new KIT or PDGFRA
      mutations or over expression of the KIT protein; target modulation due to activation of an
      alternate receptor tyrosine kinase protein with loss of KIT oncoprotein expression;
      functional resistance due to KIT or PDGFRA activation without a secondary mutation; and
      alterations in imatinib uptake by P-glycoprotein.

      This study seeks to test nilotinib alone and nilotinib in combination with imatinib in
      patients that have progressed on imatinib.

      Nilotinib is a new synthetic second-generation inhibitor of the BCR-ABL tyrosine kinase that
      competes for the ATP-bindings sites of BCR-ABL. A completed phase I trial assessed the
      activity of nilotinib alone and in combination with imatinib in patients that have progressed
      on imatinib in a population of patients with imatinib refractory and intolerant patients.
      There were rare responses, but stable disease was observed in grater than 50% of patients.

      This study is aiming to treat patients with advanced or metastatic GIST who have disease
      progression on imatinib dose escalated up to 600 mg or greater. The rationale for exploring
      Nilotinib in this setting is to determine if it has therapeutic efficacy, with potentially
      less toxicity than the current standard of care for second line therapy. In addition, since
      it is not uncommon to see progression of some metastatic GIST lesions on imatinib, while
      others remain controlled, adding nilotinib may treat the progressing lesions while imatinib
      continues to control the areas without disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Novartis is ending their research program for Nilotinib in GIST.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months until death or for 5 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression. It will be determined for both RECIST (Response Evaluation Criteria in Solid Tumors) and CHOI criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging</measure>
    <time_frame>Every 8 weeks for up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>GIST</condition>
  <condition>Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nilotinib 400 mg po bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib + Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nilotinib 400 mg BID with Imatinib 400 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib 400 mg po bid</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib with Imatinib</intervention_name>
    <description>Nilotinib 400 mg po BID Imatinib 400 mg po daily</description>
    <arm_group_label>Nilotinib + Imatinib</arm_group_label>
    <other_name>Tasigna</other_name>
    <other_name>Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed GIST.

          -  advanced/metastatic GIST.

          -  experienced failure of prior treatment with imatinib 600-800 mg per day defined by
             progression of disease according to RECIST criteria during treatment. Radiographic
             evidence of PD on imatinib must be confirmed by the Investigator prior to enrollment.

          -  May have focal progression of disease including a new enhancing nodular focus within a
             pre-existing tumor nodule; such a nodule should be considered measurable by standard
             RECIST criteria.

          -  measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) as &gt;20 mm with conventional
             techniques or as &gt;10 mm with spiral CT scan.

          -  At least 4 weeks since prior therapy with imatinib &amp; resolution of all acute toxic
             effects of the prior therapy or surgical procedure to grade â‰¤1.

          -  Age &gt;18 years.

          -  ECOG performance status 0-2.

          -  Normal organ and marrow function as defined below:

               -  ANC &gt;1,500/mcL

               -  Platelets &gt;100,000/mcL

               -  Total bilirubin &lt; or equal to 1.5 X ULN

               -  AST(SGOT)/ALT(SGPT) &lt; or equal to 2.5 X ULN OR &lt; or equal to 5.0 X ULN if
                  considered due to tumor

               -  Amylase/Lipase &lt; or equal to 1.5 X ULN

               -  Alkaline Phosphatase &lt; or equal to 2.5 X ULN or &lt;/= 5 X ULN if considered tumor
                  related.

               -  Potassium, magnesium, calcium, phosphorus, creatinine WNL prior to randomization

               -  OR

               -  Creatinine clearance of &gt; 50 calculated by cockroft-gault formula

          -  WOCBP must have negative pregnancy test within 7 days of first treatment and use
             appropriate contraception.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Have received nilotinib or additional tyrosine kinase inhibitors or additional
             targeted therapies (except for imatinib).

          -  May not be receiving any other investigational agents within 4 weeks before treatment.

          -  Prior or concomitant malignancies (with a relapse in the last 5 years or requiring
             active treatment) other than GIST and with exception of previous or concomitant basal
             cell skin, previous cervical carcinoma in situ.

          -  Impaired cardiac function, including any one of the following:

        Complete left bundle branch block. Ventricular paced cardiac pacemaker. Congenital long QT
        syndrome or family history of long QT syndrome. History of or presence of symptomatic
        ventricular or atrial tachyarrhythmias. Clinically significant resting bradycardia (&lt; 50
        beats per minute). QTc &gt; 480 msec on screening ECG (using the QTcF formula). If QTc &gt; 480
        msec and electrolytes are not within normal ranges (electrolytes should be corrected and
        then the patient rescreened for QTc).

        Right bundle branch block plus left anterior hemiblock, bifascicular block. Myocardial
        infarction within 12 months prior to Visit 1. Other clinically significant heart diseases
        (e.g., unstable angina, congestive heart failure or uncontrolled hypertension).

        Severe and/or uncontrolled concurrent medical disease that could cause unacceptable safety
        risks or compromise compliance with protocol e.g. impairment of GI function, or GI disease
        that may significantly alter absorption of study drugs; uncontrolled diabetes; active
        infections; psychiatric illness/social situation that would limit compliance with study
        requirements.

          -  Inability to remain laying down in PET scanner for up to one hour.

          -  Use of any medications that prolong the QT interval and CYP3A4 inhibitors if treatment
             cannot be either safely discontinued or switched to a different medication prior to
             starting study drug administration.

          -  Major surgery â‰¤ 2 weeks prior to Visit 1 or who have not recovered from side effects
             of such surgery.

          -  Known history of noncompliance to medical regimens or inability/unwillingness to
             return for scheduled visits, patients who are pregnant or breast feeding, patients
             unwilling or unable to comply with the requirements for the protocol.

          -  Known chronic liver disease (i.e., chronic active, hepatitis, and cirrhosis).

          -  Known diagnosis of HIV, currently taking combination antiretroviral therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siteman Cancer Center, Washington University School of Mediciine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>May 7, 2013</results_first_submitted>
  <results_first_submitted_qc>January 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Imatinib Resistance</keyword>
  <keyword>GIST</keyword>
  <keyword>Advanced Disease</keyword>
  <keyword>Nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During the period of February 2, 2009 through May 26, 2011, recruitment occur at oncology hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib</title>
          <description>Nilotinib 400 mg po bid</description>
        </group>
        <group group_id="P2">
          <title>Nilotinib + Imatinib</title>
          <description>Nilotinib 400 mg BID with Imatinib 400 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib</title>
          <description>Nilotinib 400 mg po bid</description>
        </group>
        <group group_id="B2">
          <title>Nilotinib + Imatinib</title>
          <description>Nilotinib 400 mg BID with Imatinib 400 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression. It will be determined for both RECIST (Response Evaluation Criteria in Solid Tumors) and CHOI criteria.</description>
        <time_frame>6 months until death or for 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Nilotinib 400 mg by mouth (PO), twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib + Imatinib</title>
            <description>Nilotinib 400 mg twice daily (BID) with Imatinib 400 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression. It will be determined for both RECIST (Response Evaluation Criteria in Solid Tumors) and CHOI criteria.</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="5.6"/>
                    <measurement group_id="O2" value="16" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging</title>
        <time_frame>Every 8 weeks for up to 5 years</time_frame>
        <population>Too few participants to provide meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Nilotinib 400 mg po bid</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib + Imatinib</title>
            <description>Nilotinib 400 mg BID with Imatinib 400 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging</title>
          <population>Too few participants to provide meaningful analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib</title>
          <description>Nilotinib 400 mg po bid</description>
        </group>
        <group group_id="E2">
          <title>Nilotinib + Imatinib</title>
          <description>Nilotinib 400 mg BID with Imatinib 400 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial ended early due to industry support of provision of nilotinib was discontinued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret von Mehren, Principal Investigator</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-728-4300</phone>
      <email>margaret.vonmehren@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

